Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 4, 2024, at 7:00 a.m. Eastern Time.

This event presents an opportunity for investors and interested parties to gain insights into Nautilus's innovative proteomics platform. A live and archived webcast of the presentation will be accessible through the 'Investors' section of the company's website at www.nautilus.bio, allowing for widespread access to the discussion.

News Market Reaction – NAUT

-2.18%

-2.18% Session move

In the trading session that priced this news, NAUT declined 2.18%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.

Nautilus management is scheduled to participate in a fireside chat on Wednesday, September 4, 2024, at 7:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

FAQ

When is Nautilus Biotechnology (NAUT) participating in the Morgan Stanley Healthcare Conference?

Nautilus Biotechnology (NAUT) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, with a fireside chat scheduled for 7:00 a.m. Eastern Time.

Where can I watch the webcast of Nautilus Biotechnology's (NAUT) presentation at the Morgan Stanley conference?

The live and archived webcast of Nautilus Biotechnology's (NAUT) presentation can be accessed on the 'Investors' section of the company's website at www.nautilus.bio.

What is Nautilus Biotechnology's (NAUT) main focus in biotechnology?

Nautilus Biotechnology (NAUT) is pioneering a single-molecule proteome analysis platform, focusing on innovative proteomics technology.

Is Nautilus Biotechnology (NAUT) a publicly traded company?

Yes, Nautilus Biotechnology is publicly traded on the NASDAQ stock exchange under the ticker symbol NAUT.